Company: INTS
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001567264-25-000010
Chunk: 31

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 16
Chunk 31
---
 income tax in the U.S. Federal and Connecticut jurisdictions. 

Note 15. Segments

The Company has a single segment and allocates resources based on cash resources and operating expense projections. The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023:

F-18

Years Ended December 31,20242023Research and development expenses:Clinical trial expenses:IT-01 Study (Phase 1/2 Metastatic Cancers)$(128)$984 INVINCIBLE-2 Study (Phase 2 Breast)233 402 INVINCIBLE-3 Study (Phase 3 Sarcoma)6,225 578 INVINCIBLE-4 Study (Phase 2 Breast)524 19 Other clinical trial expenses(a)223 4 Clinical trial expenses7,077 1,987 Contract manufacturing657 922 Salaries and benefits related1,379 896 Consulting & Other(b)143 267 Stock-based compensation1,240 714 Research and development expenses10,496 4,786 General and administrative expenses:Salaries and benefits related884 559 Legal fees728 423 Audit fees349 404 Consulting768 430 Insurance874 608 Other(c)653 425 Stock-based compensation1,833 684 General and administrative expenses6,089 3,533 Loss from operations(16,585)(8,319)Other segment items, net(d)317 43 Loss on debt extinguishment— (2,262)Net loss$(16,268)$(10,538)(a)Represents ancillary clinical and clinical-related costs associated with clinical studies.(b)Consulting & Other includes research and development consulting costs and travel-related costs. (c)Other includes facility expenses, office supplies, computer and software related costs, public relations costs, and travel-related costs. 

(d)Other segment items include interest income, interest expense, and foreign exchange gains and losses. 

F-19